Evidence map›Paper›PMID 28369882›Full record

ArticleInternational journal of cancer2017

Worldwide burden of cancer attributable to HPV by site, country and HPV type.

Catherine de Martel, Martyn Plummer, Jerome Vignat, Silvia Franceschi

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05566106 (Anal Follow-up of Patients With a Gynecological History of High-grade Lesion and More Induced HPV), which is not on this map. Cited by 1,267 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,267citing papers in PubMed, 7 pooled it
100.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05566106 recruitingnot on this mapstarted 2022, after this paper: background citation

Anal Follow-up of Patients With a Gynecological History of High-grade Lesion and More Induced HPV

TypeobservationalSponsorFondation Hôpital Saint-JosephRan2022 to 2032Enrolled1,500ConditionsHuman Papilloma Virus
3 · Its place in the literature

Who cites it

1,267 citing papers in PubMed, 7 syntheses or guidelines pooled it, 2,232 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With Men.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Trial
  10. Trial
  11. Immunogenicity and safety of co-administeredFrontiers in immunology · 2026
    Trial
  12. Trial
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

1,207 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Catherine de MartelInternational Agency for Research on Cancer, Lyon, France.ORCID 0000-0002-3642-277X
Martyn PlummerInternational Agency for Research on Cancer, Lyon, France.
Jerome VignatInternational Agency for Research on Cancer, Lyon, France.
Silvia FranceschiInternational Agency for Research on Cancer, Lyon, France.
Centre international de recherche sur le cancer · FR

Funding

World Health Organization 001
6 · The paper itself

Abstract

HPV is the cause of almost all cervical cancer and is responsible for a substantial fraction of other anogenital cancers and oropharyngeal cancers. Understanding the HPV-attributable cancer burden can boost programs of HPV vaccination and HPV-based cervical screening. Attributable fractions (AFs) and the relative contributions of different HPV types were derived from published studies reporting on the prevalence of transforming HPV infection in cancer tissue. Maps of age-standardized incidence rates of HPV-attributable cancers by country from GLOBOCAN 2012 data are shown separately for the cervix, other anogenital tract and head and neck cancers. The relative contribution of HPV16/18 and HPV6/11/16/18/31/33/45/52/58 was also estimated. 4.5% of all cancers worldwide (630,000 new cancer cases per year) are attributable to HPV: 8.6% in women and 0.8% in men. AF in women ranges from <3% in Australia/New Zealand and the USA to >20% in India and sub-Saharan Africa. Cervix accounts for 83% of HPV-attributable cancer, two-thirds of which occur in less developed countries. Other HPV-attributable anogenital cancer includes 8,500 vulva; 12,000 vagina; 35,000 anus (half occurring in men) and 13,000 penis. In the head and neck, HPV-attributable cancers represent 38,000 cases of which 21,000 are oropharyngeal cancers occurring in more developed countries. The relative contributions of HPV16/18 and HPV6/11/16/18/31/33/45/52/58 are 73% and 90%, respectively. Universal access to vaccination is the key to avoiding most cases of HPV-attributable cancer. The preponderant burden of HPV16/18 and the possibility of cross-protection emphasize the importance of the introduction of more affordable vaccines in less developed countries.

Indexed as

Africa South of the SaharaAnus NeoplasmsAustraliaFemaleHuman papillomavirus 16Human papillomavirus 18HumansIndiaMaleNew ZealandOropharyngeal NeoplasmsPapillomavirus InfectionsPenile NeoplasmsPrevalenceSex CharacteristicsUnited Statesattributable fractioncancerhuman papillomaviruspreventionvaccine

Identifiers

PMID28369882
PMCPMC5520228
OpenAlexW2605365014

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.